This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EHC vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
A faster-than-expected recovery in base business and stabilized demand for COVID-19 testing instill optimism in Quest Diagnostics (DGX).
Inari Medical (NARI) Q2 Earnings Lag, Revenues Top Estimates
by Zacks Equity Research
Inari Medical's (NARI) second-quarter 2021 results benefit from significant revenue growth and gross margin expansion.
STERIS (STE) Q1 Earnings Beat Estimates, 2022 Guidance Up
by Zacks Equity Research
STERIS (STE) reported better-than-expected revenues for first-quarter fiscal 2022 on strong segmental performance driving the top line.
ShockWave Medical (SWAV) Q2 Earnings, Revenues Top Estimates
by Zacks Equity Research
ShockWave Medical's (SWAV) robust performance across product lines and geographies drive its Q2 sales.
SmileDirectClub (SDC) Q2 Loss Wider Than Expected, Margin Up
by Zacks Equity Research
SmileDirectClub (SDC) registered year-over-year revenue growth in the second quarter, driven primarily by unique aligner shipment.
Syneos Health (SYNH) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Syneos Health (SYNH) reported better-than-expected revenues for the second quarter of 2021 on strong segmental performance.
Allscripts' (MDRX) Shares Up Following Q2 Earnings Beat
by Zacks Equity Research
Allscripts' (MDRX) robust Q2 results demonstrate its strength in Client services segment.
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
Glaukos (GKOS) Stock Gains 0.1% Following Lower Loss in Q2
by Zacks Equity Research
Despite reporting second-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.
AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
Nevro (NVRO) Q2 Earnings Surpass Estimates, Revenues Lag
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues rise on a year-over-year basis in Q2 despite pandemic-led business challenges.
Quidel (QDEL) Q2 Earnings Fall Shy of Estimates, Margins Down
by Zacks Equity Research
Quidel's (QDEL) dismal Q2 performance stems from lower revenues across majority of its product categories.
Illumina (ILMN) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Year-over-year improvement in segmental revenues in Q2 across all geographies exceeds Illumina's (ILMN) expectations.
ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Increased demand for sleep devices and masks, including recovery of core sleep patient flow, drove ResMed's (RMD) fiscal fourth-quarter growth.
Insulet (PODD) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Insulet (PODD) reports better-than-expected revenues for second-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
Inogen (INGN) Stock Loses 26.7% In Spite of Q2 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.
LHC Group (LHCG) Stock Loses 11.9% Despite Q2 Earnings Beat
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from organic growth in both home health and hospice admissions.
Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
BD (BDX) Beats on Q3 Earnings and Revenues, Ups '21 View
by Zacks Equity Research
Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal third quarter, thus driving up the overall top line.
Surmodics' (SRDX) Q3 Earnings, Revenues Fall Shy of Estimates
by Zacks Equity Research
Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.
New Strong Buy Stocks for August 5th
by Zacks Equity Research
ARCB, EHC, MRO, TTMI, and ON have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2021.
Tandem Diabetes (TNDM) Q2 Earnings Rise Y/Y, Sales View Up
by Zacks Equity Research
Tandem Diabetes (TNDM) reports better-than-expected revenues for second quarter 2021 on strong domestic and international pump shipments driving the top line.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.
Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected
by Zacks Equity Research
Strength in both coronary and peripheral segments drove Cardiovascular Systems' (CSII) revenues in the fiscal fourth quarter.